Does oral N-acetylcysteine reduce contrast-induced renal injury in patients with peripheral arterial disease undergoing peripheral angiography? A randomized-controlled study

Angiology. 2011 Apr;62(3):225-30. doi: 10.1177/0003319710377078. Epub 2010 Aug 3.

Abstract

The nephroprotective role of N-acetylcysteine (NAC) against contrast-induced nephropathy (CIN) in patients undergoing peripheral arterial angiography remains unclear. A total of 40 patients undergoing peripheral arterial angiography were randomized to receive intravenous (iv) hydration only (group 1) or oral NAC in addition to iv hydration (group 2; ISRCTN: 35882618). Primary outcome was reduction in the elevation of urinary retinol binding protein (RBP), albumin-creatinine ratio (ACR), and serum creatinine (serC). Groups 1 and 2 had equivocal percentage reduction in RBP and ACR levels from baseline (P = .80 and .30). A significant reduction in serC was, however, observed with NAC by third postprocedure day (P = .04). One patient in the treatment arm developed CIN compared with 3 patients in the control group (P = .33). Equivocal changes in RBP and ACR levels by both treatments seem to indicate that either is equally effective in affording renal protection.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Acetylcysteine / pharmacology*
  • Aged
  • Albuminuria / etiology
  • Angiography*
  • Biomarkers / blood
  • Biomarkers / urine
  • Contrast Media / adverse effects*
  • Creatinine / blood
  • Creatinine / urine
  • Female
  • Humans
  • Kidney Diseases / chemically induced*
  • Kidney Diseases / prevention & control*
  • Male
  • Peripheral Arterial Disease / diagnostic imaging*
  • Retinol-Binding Proteins, Cellular / urine
  • Statistics, Nonparametric
  • Treatment Outcome

Substances

  • Biomarkers
  • Contrast Media
  • Retinol-Binding Proteins, Cellular
  • Creatinine
  • Acetylcysteine

Associated data

  • ISRCTN/ISRCTN35882618